Amgen gets CHMP negative opinion for Vectibix marketing authorization application
Linkedin

Amgen gets CHMP negative opinion for Vectibix marketing authorization application

London : United Kingdom | Mar 21, 2011 at 1:34 AM PDT
Source: Pharmaceutical Industry News
XX XX
Views: Pending
 
US Food and Drug Administration (FDA) for the treatment of mCRC. Vectibix combined with chemotherapy offers an important treatment option for mCRC patients. FULL ARTICLE AT Pharmaceutical Industry News
 
  • Clear
  • Share:
  • Share
  • Clear
  • Clear
  • Clear
  • Clear
 
  • Credibility
  • Wait... Flag
 
 
Advertisement
 

More From Allvoices



Use of this site is governed by our Terms of Use Agreement and Privacy Policy.

© Allvoices, Inc. 2008-2014. All rights reserved. Powered by PulsePoint.